Lecanemab will be marketed as Leqembi, the FDA statement said. It has shown “potential” as an Alzheimer’s disease treatment by appearing to slow progression, according to Phase 3 trial ...

The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on ...

The drug, a monoclonal antibody called lecanemab, dominated last week's Clinical Trials on Alzheimer's Disease meeting in San Francisco. At the meeting, researchers presented results of a study of ...

However, a new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10-13 months in the early stage. Usually, in Alzheimer's disease ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

The treatment, lecanemab, was found to triple the risk of death within a year, compared with dementia sufferers not prescribed the drug. Previous studies have suggested it slowed the progression ...

A resident of a nursing home plays the game "Memory" on a care ward and puts pairs of cards together. The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong and Israel, and is being marketed in the U.S., Japan and China. AD currently affects 6.9 million people in ...

NICE's public consultation on donanemab and lecanemab closes on March 27, 2025, with final recommendations to follow after stakeholder input The appraisal committee maintains that both treatments ...